{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T09:53:18Z","timestamp":1776678798860,"version":"3.51.2"},"reference-count":9,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objective: To characterize the distribution of FCR severity across survivorship time intervals in bladder cancer survivors. Methods: A cross-sectional study of 79 patients utilized the validated 9-item FCR Inventory-Short Form (FCRI-SF) to assess overall FCR severity. Primary analysis employed Spearman\u2019s correlation coefficient to evaluate the relationship between time elapsed since the first procedure and total FCR scores. Patients were stratified into four temporal groups (&lt;1, 1\u20132, 2\u20135, and &gt;5 years). Inter-group variability in FCR scores was assessed using Levene\u2019s test for equality of variances. Subgroup analyses compared FCR scores across clinical subgroups, including tumor grade and smoking history, using the Mann\u2013Whitney U test. Multivariate logistic regression identified independent predictors of clinically significant FCR (total score \u226513). Results: Median patient age was 72.0 years (IQR 66.0\u201378.0), with a median of 24.0 months post-diagnosis. Clinically significant FCR (score \u226513) was prevalent in 55.7% of the cohort. Spearman correlation analysis revealed no significant relationship between months elapsed and FCR severity (rho = 0.068, p = 0.552). Patients in the 12\u201324 month window exhibited the highest variability (Levene\u2019s test, p = 0.058), representing a period of clinical divergence. High-Grade disease and smoking cessation motivated by diagnosis were associated with higher FCR scores. In the multivariate logistic regression model, history of tumor recurrence was the sole independent predictor of clinically significant FCR (aOR 3.28, 95% CI 1.11\u20139.68, p = 0.031), whereas age and gender were not significantly associated. Conclusions: FCR severity did not demonstrate a significant association with time elapsed since diagnosis in this cross-sectional sample. The 1\u20132 year interval demonstrated greater inter-individual variability in FCR scores. Findings highlight the need for long-term, structured survivorship support, particularly targeting the 12\u201324 month post-diagnosis window.<\/jats:p>","DOI":"10.3390\/jcm15083116","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:24:23Z","timestamp":1776673463000},"page":"3116","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Burden of Worry: Fear of Cancer Recurrence Across Bladder Cancer Survivorship Phases\u2014A Cross-Sectional Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9957-0390","authenticated-orcid":false,"given":"Dor","family":"Golomb","sequence":"first","affiliation":[{"name":"Department of Urology, Assuta Ashdod University Hospital, 7 Harefua St., Ashdod 7747629, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7493-4672","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Simard","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Universit\u00e9 du Qu\u00e9bec \u00e0 Chicoutimi, Saguenay, QC G7H 2B1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alon","family":"Eisner","sequence":"additional","affiliation":[{"name":"Department of Urology, Assuta Ashdod University Hospital, 7 Harefua St., Ashdod 7747629, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Avda","sequence":"additional","affiliation":[{"name":"Department of Urology, Assuta Ashdod University Hospital, 7 Harefua St., Ashdod 7747629, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahed","family":"Atamna","sequence":"additional","affiliation":[{"name":"Department of Urology, Assuta Ashdod University Hospital, 7 Harefua St., Ashdod 7747629, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orit","family":"Raz","sequence":"additional","affiliation":[{"name":"Department of Urology, Assuta Ashdod University Hospital, 7 Harefua St., Ashdod 7747629, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: An update","volume":"38","author":"Richters","year":"2020","journal-title":"World J. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Cookson","year":"2024","journal-title":"BMJ"},{"key":"ref_3","first-page":"97","article-title":"Mental health implications in bladder cancer patients: A review","volume":"37","author":"Pham","year":"2019","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1097\/NCC.0000000000000606","article-title":"Quality of Life in Non-Muscle-Invasive Bladder Cancer Survivors: A Systematic Review","volume":"42","author":"Jung","year":"2019","journal-title":"Cancer Nurs."},{"key":"ref_5","first-page":"241","article-title":"Fear of Cancer Recurrence Inventory: Development and initial validation of a multidimensional measure of fear of cancer recurrence","volume":"17","author":"Simard","year":"2009","journal-title":"Support. Care Cancer"},{"key":"ref_6","unstructured":"PDQ Supportive and Palliative Care Editorial Board (2025). Adjustment to Cancer: Anxiety and Distress (PDQ\u00ae), PDQ Cancer Information Summaries."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2147\/CMAR.S556758","article-title":"Fear of Cancer Recurrence and Its Associated Factors in Bladder Cancer Patients of Different Age Stages: A Cross-Sectional Study","volume":"17","author":"Li","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/pon.3114","article-title":"Factors reported to influence fear of recurrence in cancer patients: A systematic review","volume":"22","author":"Crist","year":"2013","journal-title":"Psychooncology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/3116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T09:00:19Z","timestamp":1776675619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/3116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":9,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15083116"],"URL":"https:\/\/doi.org\/10.3390\/jcm15083116","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]}}}